Monte Rosa Therapeutics Inc. (GLUE) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
321 HARRISON AVENUE BOSTON, MA 02118 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 128,101 | 54,912 | 346,071 | |||
| Cash and cash equivalents | 128,101 | 54,912 | 346,071 | |||
| Restricted cash and investments | 960 | |||||
| Other undisclosed current assets | 108,111 | 220,014 | 2,595 | |||
| Total current assets: | 236,212 | 275,886 | 348,666 | |||
| Noncurrent Assets | ||||||
| Operating lease, right-of-use asset | 28,808 | 34,832 | ||||
| Property, plant and equipment | 33,803 | 27,075 | 12,325 | |||
| Restricted cash and investments | 4,580 | 4,318 | 5,338 | |||
| Other noncurrent assets | 352 | 278 | ||||
| Total noncurrent assets: | 67,543 | 66,503 | 17,663 | |||
| TOTAL ASSETS: | 303,755 | 342,389 | 366,329 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 18,745 | 13,486 | 10,861 | |||
| Employee-related liabilities | ✕ | ✕ | ✕ | 4,303 | ||
| Accounts payable | 11,152 | 7,862 | 6,558 | |||
| Accrued liabilities | 7,593 | 5,624 | ||||
| Deferred revenue | 17,678 | |||||
| Other liabilities | 1,671 | 5,020 | 840 | |||
| Other undisclosed current liabilities | 8,498 | 7,063 | 4,937 | |||
| Total current liabilities: | 46,592 | 25,569 | 16,638 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 45,590 | 45,407 | 2,176 | |||
| Liability, pension and other postretirement and postemployment benefits | 2,713 | 1,533 | 2,176 | |||
| Operating lease, liability | 42,877 | 43,874 | ||||
| Other undisclosed noncurrent liabilities | 32,323 | |||||
| Total noncurrent liabilities: | 77,913 | 45,407 | 2,176 | |||
| Total liabilities: | 124,505 | 70,976 | 18,814 | |||
| Temporary equity, carrying amount | 347,515 | |||||
| Equity | ||||||
| Equity, attributable to parent | 179,250 | 271,413 | 347,515 | |||
| Common stock | 5 | 5 | 5 | |||
| Additional paid in capital | 547,857 | 503,696 | 471,566 | |||
| Accumulated other comprehensive loss | (2,724) | (1,752) | (2,021) | |||
| Accumulated deficit | (365,888) | (230,536) | (122,035) | |||
| Other undisclosed equity | (347,515) | |||||
| Total equity: | 179,250 | 271,413 | ||||
| TOTAL LIABILITIES AND EQUITY: | 303,755 | 342,389 | 366,329 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues (Other undisclosed Revenues) | |||||
| Gross profit: | |||||
| Operating expenses | (143,311) | (112,384) | (72,882) | ||
| Operating loss: | (143,311) | (112,384) | (72,882) | ||
| Nonoperating income (expense) | 8,297 | 3,883 | (1,076) | ||
| Gain (loss), foreign currency transaction, before tax | (930) | 10 | (162) | ||
| Interest and debt expense | (198) | (19) | |||
| Other undisclosed loss from continuing operations before equity method investments, income taxes | |||||
| Loss from continuing operations before equity method investments, income taxes: | (135,212) | (108,520) | (73,958) | ||
| Other undisclosed income from continuing operations before income taxes | 198 | ||||
| Loss from continuing operations before income taxes: | (135,014) | (108,520) | (73,958) | ||
| Income tax expense | (338) | ||||
| Loss from continuing operations: | (135,352) | (108,520) | (73,958) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (73,958) | |
| Other undisclosed net income | 19 | ||||
| Net loss available to common stockholders, diluted: | (135,352) | (108,501) | (73,958) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net loss: | (135,352) | (108,501) | (73,958) | ||
| Other comprehensive income (loss) | 1,000 | 300 | (1,000) | ||
| Other undisclosed comprehensive income | |||||
| Comprehensive loss: | (134,352) | (108,201) | (74,958) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (1,972) | (31) | 35 | ||
| Comprehensive loss, net of tax, attributable to parent: | (136,324) | (108,232) | (74,923) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.